论文部分内容阅读
作者回顾口服英卡胺对可能致死性(约占80%)和良性室性心律失常的疗效.其标准为Holter监测示:原有的室(性)早(搏)(≥30次/h)减少≥75%和/或持续性室(性心动过)速完全消失.(1)多中心口服剂量调整试验包括110例患者.英卡胺剂量为25～75mg,qid.(2)3个中心参加的低剂量试验,由35例患者参加.英卡胺剂量依次为10～20～30mg,qid.(3)8个中心参加的双盲、平行、安慰剂对照试验.125例患者随机分组后服用安慰剂,英卡胺10、25或50mg.该试验的剂量反应曲线的下端为英卡胺25mg,tid;在此最低有效剂
The authors review the efficacy of oral enkaamine on potentially lethal (about 80%) and benign ventricular arrhythmias. The criteria for this are Holter monitoring: the original ventricular premature beats (≥30 beats / h) A decrease of ≥75% and / or a sustained disappearance of persistent ventricular tachycardia. (1) The multicentre oral dose adjustment trial consisted of 110 patients with doses of 25 to 75 mg of INK (qid. (2) 3 centers Participants of the low-dose trial were enrolled in 35 patients with double-blind, parallel, placebo-controlled trials of 8 to 15 mg of enkavan followed by qid. (3) A randomized controlled trial of 125 patients randomized Placebo, Invocavirus 10, 25, or 50 mg The lower end of the dose response curve for this trial was Invastridine 25 mg, tid; at this minimum dose